Metastatic cancer, the spread of cancer cells to distant sites, is a leading cause of cancer-related deaths. Current methods for monitoring and analyzing circulating tumor cells (CTCs) in the bloodstream are often invasive, time-consuming, and lack the sensitivity needed for early detection of metastasis.

This startup is developing a medical device designed to selectively capture and analyze circulating tumor cells (CTCs) directly from a patient's bloodstream. The device uses a microfluidic platform to efficiently filter and isolate CTCs, providing a non-invasive method for monitoring cancer progression and treatment response. By analyzing the captured CTCs, clinicians can gain valuable insights into the molecular characteristics of the tumor, identify potential drug targets, and personalize treatment strategies. The technology aims to improve the management of metastatic cancer by enabling earlier detection, more precise monitoring, and targeted therapeutic interventions.

Microfluidic chip for high-throughput capture of CTCs from whole blood samples

Non-invasive blood draw procedure, minimizing patient discomfort

High sensitivity and specificity for CTC isolation, even at low concentrations

Downstream analysis capabilities, including single-cell sequencing and proteomic profiling

Automated data analysis and reporting software for streamlined interpretation of results

The primary target audience includes oncologists, pathologists, and researchers involved in cancer diagnostics, treatment monitoring, and drug development.